P04233 (HG2A_HUMAN) Homo sapiens (Human)
HLA class II histocompatibility antigen gamma chain UniProtKBInterProSTRINGInteractive Modelling
Available Structures
23 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Cryo-EM structure of human invariant chain in complex with HLA-DQ |
Heteromer P01909; P01920; | 100 | 3×NAG; | |||
| CRYSTAL STRUCTURE OF MHC CLASS II ASSOCIATED P41 II FRAGMENT IN COMPLEX WITH CATHEPSIN L |
Heteromer P07711; | 100 | 1×NAG; | |||
| Cryo-EM structure of human invariant chain in complex with HLA-DR15 |
Heteromer P01903; P01911; | 100 | ||||
| Crystal Structure of HLA-DR1 with CLIP102-120 |
Heteromer P01903; P01911; | 100 | 2×GOL; 1×FMT; | |||
| HLA-DR1 with CLIP102-120(M107W) |
Heteromer P01903; P01911; | 93.33 | ||||
| MHC-II dynamics are maintained in HLA-DR allotypes to ensure catalyzed peptide exchange |
Heteromer A0A4E9DJJ3; P01903; | 100 | 6×EDO; | |||
| Crystal structure of murine class II MHC I-Ab in complex with a human CLIP peptide |
Heteromer P14434; P14483; | 100 | 2×NAG; | |||
| HLA-DR1 with covalently linked CLIP106-120 in reversed orientation |
Heteromer P01903; P01911; | 100 | 2×GOL; | |||
| HLA-DR1 with covalently linked CLIP106-120 in canonical orientation |
Heteromer P01903; P01911; | 100.0 | 4×GOL; | |||
| Crystal Structure of HLA-DR1 with CLIP106-120, flipped peptide orientation |
Heteromer P01903; P01911; | 100 | ||||
| Crystal Structure of HLA-DR1 with CLIP106-120, canonical peptide orientation |
Heteromer P01903; P01911; | 100 | ||||
| THE STRUCTURE OF AN INTERMEDIATE IN CLASS II MHC MATURATION: CLIP BOUND TO HLA-DR3 |
Heteromer P01903; P01911; | 100 | 2×NAG; | |||
| Structure of LAG3 bound to the MHC class II molecule I-A(b) |
Heteromer P14434; P14483; Q61790; | 100 | 4×NAG; | |||
| Structure of LAG3 loop1 deletion bound to the MHC class II molecule I-A(b) |
Heteromer P14434; P14483; Q61790; | 100 | 4×NAG; | |||
| MHC-II dynamics are maintained in HLA-DR allotypes to ensure catalyzed peptide exchange |
Heteromer A0A1V1IGJ9; P01903; | 100 | 9×EDO; 1×FLC; | |||
| F54C HLA-DR1 bound with CLIP peptide |
Heteromer P01903; P01911; | 100 | ||||
| HLA-DR1 bound with CLIP peptide |
Heteromer P01903; P01911; | 100 | ||||
| Crystal structure of HLA-DQ2.5-CLIP1 at 2.73 resolution |
Heteromer P01909; Q5Y7D3; | 100 | ||||
| MHC-II dynamics are maintained in HLA-DR allotypes to ensure catalyzed peptide exchange |
Heteromer D7RIG5; P01903; | 100 | 9×EDO; | |||
| Crystal structure of HLA-DQ2.5-CLIP2 |
Heteromer P01909; Q5Y7D3; | 100 | ||||
| Engineered peptide-specific binder in complex with HLA-DR1/CLIP |
Heteromer D7RIG0; P01903; Q48898; | 100 | 3×NAG; | |||
| HLA-DR ANTIGENS ASSOCIATED INVARIANT CHAIN | homo-3-mer | 100 | ||||
| NMR structure of P41icf, a potent inhibitor of human cathepsin L | monomer | 100 | ||||
3 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8vsp.1.I | monomer | 0.66 | 100.00 | |||
| 1iie.1.A | homo-3-mer | 0.66 | 100.00 | |||
| 8d6u.1.A | monomer | 0.56 | 40.79 | |||
7 SWISS-MODEL models built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 8vsp.1.C | monomer | 0.68 | 100.00 | |||
| Isoform 2 | 1iie.1.A | homo-3-mer | 0.61 | 100.00 | |||
| Isoform 3 | 8vsp.1.C | monomer | 0.64 | 96.05 | |||
| Isoform 4 | 8vsp.1.I | monomer | 0.67 | 100.00 | |||
| Isoform 4 | 8d6u.1.A | monomer | 0.56 | 40.79 | |||
| Isoform 5 | 8vsp.1.C | monomer | 0.67 | 100.00 | |||
| Isoform 5 | 1iie.1.A | homo-3-mer | 0.61 | 100.00 | |||